# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing mu...
Cantor Fitzgerald analyst Olivia Brayer reiterates Bristol-Myers Squibb (NYSE:BMY) with a Neutral and maintains $50 price ta...
Objective response rate (ORR) 29%, confirmed ORR (cORR) 25%, disease control rate (DCR) of 53% and tumor shrinkage rate of 53% ...
These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for o...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.